Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study

Abstract

Isolated distal deep vein thrombosis (IDDVT) is presumed to be more benign than proximal DVT (PDVT) or pulmonary embolism (PE), suggesting a need for different management approaches. This subgroup analysis of the RE-COVERY DVT/PE global, observational study investigated patient characteristics, hospitalization details, and anticoagulant therapy in patients with IDDVT in real-world settings in 34 countries enrolled from January 2016 to May 2017. Data were analyzed descriptively according to the type and location of the index venous thromboembolism (VTE): IDDVT, PDVT ± distal DVT (DDVT), and PE ± DVT. Of the 6,095 eligible patients, 323 with DVT located outside the lower limb and no PE were excluded. Of the remaining 5,772 patients, 17.6% had IDDVT, 39.9% had PDVT ± DDVT, and 42.5% had PE ± DVT. IDDVT patients were younger and had fewer risk factors for VTE than the other groups. Other comorbidities were less frequent in the IDDVT group, except for varicose veins, superficial thrombophlebitis, and venous insufficiency. IDDVT patients were less likely to be diagnosed in an emergency department (22.3 vs. 29.7% for PDVT ± DDVT and 45.4% for PE ± DVT) or hospitalized for VTE (29.2 vs. 48.5% for PDVT ± DDVT and 75.0% for PE ± DVT). At hospital discharge or 14 days after diagnosis (whichever was later), non–vitamin K antagonist oral anticoagulants were the most commonly used anticoagulants (55.6% for IDDVT, 54.7% for PDVT ± DDVT, and 52.8% for PE ± DVT). Although differences in patient characteristics, risk factors, and clinical management were identified, anticoagulant treatment of IDDVT was almost equal to that of PDVT or PE. Prospective studies should investigate whether, in a global perspective, this is an appropriate use of anticoagulants.

Keywords

anticoagulants - venous thrombosis - distal deep vein thrombosis - direct thrombin inhibitors - pulmonary embolism

Note

Trial registration number (ClinicalTrials.gov) is NCT02596230.

Authors' Contributions

S.S. was responsible for the concept of the secondary analyses presented in this manuscript. W.T. was responsible for the data analysis. All authors were responsible for the study concept and design; interpretation of the data; preparation, review, or approval of the manuscript; revision of intellectual content; and the decision to submit the manuscript for publication.

Publikationsverlauf

Artikel online veröffentlicht:
10. Mai 2021

• References

• 1 Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38 (4, Suppl): S495-S501
• 2 Palareti G, Cosmi B, Lessiani G. et al. Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. Thromb Haemost 2010; 104 (05) 1063-1070
• 3 Palareti G, Schellong S. Isolated distal deep vein thrombosis: what we know and what we are doing. J Thromb Haemost 2012; 10 (01) 11-19
• 4 Righini M, Paris S, Le Gal G, Laroche JP, Perrier A, Bounameaux H. Clinical relevance of distal deep vein thrombosis. Review of literature data. Thromb Haemost 2006; 95 (01) 56-64
• 5 Robert-Ebadi H, Righini M. Should we diagnose and treat distal deep vein thrombosis?. Hematology (Am Soc Hematol Educ Program) 2017; 2017 (01) 231-236
• 6 Schellong SM. Distal DVT: worth diagnosing? Yes. J Thromb Haemost 2007; 5 (Suppl. 01) 51-54
• 7 Cogo A, Lensing AW, Koopman MM. et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ 1998; 316 (7124): 17-20
• 8 Philbrick JT, Becker DM. Calf deep venous thrombosis. A wolf in sheep's clothing?. Arch Intern Med 1988; 148 (10) 2131-2138
• 9 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease. Chest 2016; 149 (02) 315-352
• 10 Mazzolai L, Aboyans V, Ageno W. et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J 2018; 39 (47) 4208-4218
• 11 Ageno W, Casella IB, Han CK. et al. RE-COVERY DVT/PE: rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost 2017; 117 (02) 415-421
• 12 Goldhaber SZ, Ageno W, Casella IB. et al. Profile of patients diagnosed with acute venous thromboembolism in routine clinical practice: the RE-COVERY DVT/PE study. Am J Med 2020; 133 (08) 936-945
• 13 Barco S, Corti M, Trinchero A. et al. Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism. J Thromb Haemost 2017; 15 (07) 1436-1442
• 14 Galanaud JP, Quenet S, Rivron-Guillot K. et al; RIETE Investigators. Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis vs. proximal deep vein thrombosis in 11 086 patients. J Thromb Haemost 2009; 7 (12) 2028-2034
• 15 Galanaud JP, Sevestre-Pietri MA, Bosson JL. et al; OPTIMEV-SFMV Investigators. Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study. Thromb Haemost 2009; 102 (03) 493-500
• 16 Schellong SM, Goldhaber SZ, Weitz JI. et al. Isolated distal deep vein thrombosis: perspectives from the GARFIELD-VTE registry. Thromb Haemost 2019; 119 (10) 1675-1685
• 17 Rothman KJ. A show of confidence. N Engl J Med 1978; 299 (24) 1362-1363
• 18 Galanaud JP, Sevestre MA, Pernod G. et al. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study. J Thromb Haemost 2017; 15 (05) 907-916
• 19 Galanaud JP, Sevestre MA, Genty C. et al; OPTIMEV-SFMV Investigators. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. J Thromb Haemost 2014; 12 (04) 436-443
• 20 Barco S, Klok FA, Mahé I. et al; RIETE Investigators. Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis. Thromb Res 2019; 173: 166-171
• 21 Galanaud JP, Bosson JL, Quéré I. Risk factors and early outcomes of patients with symptomatic distal vs. proximal deep-vein thrombosis. Curr Opin Pulm Med 2011; 17 (05) 387-391
• 22 Schulman S, Kakkar AK, Goldhaber SZ. et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772